Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Kivu Bioscience Inc.
SEED Therapeutics, Inc.
MacroGenics
UNC Lineberger Comprehensive Cancer Center
Solve Therapeutics
National Institutes of Health Clinical Center (CC)
Blueprint Medicines Corporation
M.D. Anderson Cancer Center
NextPoint Therapeutics, Inc.
Agenus Inc.
Brown University
Xencor, Inc.
Prelude Therapeutics
Celon Pharma SA
Corvus Pharmaceuticals, Inc.
Merrimack Pharmaceuticals
Masonic Cancer Center, University of Minnesota
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)